- Clinical Technology
- Adult Immunization
- Hepatology
- Pediatric Immunization
- Screening
- Psychiatry
- Allergy
- Women's Health
- Cardiology
- Pediatrics
- Dermatology
- Endocrinology
- Pain Management
- Gastroenterology
- Infectious Disease
- Obesity Medicine
- Rheumatology
- Nephrology
- Neurology
- Pulmonology
New Data at IAS 2025 Underscore Real-World Success of Long-Acting Injectable HIV Therapies
New findings showcase the transformative impact of long-acting injectable therapies for effective HIV treatment and prevention.
©Ezume Images/AdobeStock
New data presented at the 2025 International AIDS Society (IAS) Conference highlight the effectiveness of long-acting injectable cabotegravir-based regimens for both HIV treatment and prevention.
Real-world and implementation data showed sustained virologic suppression in treatment-experienced and -naive populations receiving cabotegravir plus rilpivirine, as well as strong uptake and adherence to long-acting cabotegravir for pre-exposure prophylaxis (PrEP), particularly among Black women and transgender individuals—groups disproportionately affected by HIV.
“Our extensive real-world insights about CAB+RPV LA for HIV treatment and CAB LA for HIV prevention demonstrate how long-acting injectables are redefining the way we approach HIV care and management in broad populations," Jean van Wyk, MBChB, MFPM, chief medical officer, ViiV Healthcare, said in a press release. "The new real-world and implementation data at IAS 2025 further reinforce their effectiveness, safety and tolerability, and underscore our commitment to delivering therapies that meet the evolving needs of people impacted by HIV, offering flexibility and choice beyond daily oral treatment.”
New phase IIIb data from the VOLITION study evaluated treatment-naive adults who achieved rapid viral suppression on dolutegravir/lamivudine (Dovato, ViiV) and subsequently switched to CAB+RPV LA. Results highlighted a strong patient preference for long-acting injectable therapy.
Additionally, real-world studies—including COMBINE-2, CARLOS, and BEYOND—demonstrated sustained virologic suppression, adherence, and patient-reported satisfaction with CAB+RPV LA across diverse populations. Interim findings from the OPERA cohort showed effectiveness even among treatment-experienced individuals initiating therapy with detectable viral loads.
Implementation data from the PILLAR and EBONI studies examined acceptability and use of cabotegravir LA for PrEP in men who have sex with men, transgender men, and Black women. Results from both studies support the practicality of integrating long-acting PrEP into community health settings and the value of tailored provider education and patient engagement strategies.
Additional VOLITION data evaluated the use of dolutegravir/lamivudine (DTG/3TC) for rapid virologic suppression in newly diagnosed individuals. Data from investigator-led studies D2ARLING and SUNGURA explored DTG/3TC use in people with transmitted drug resistance mutations and older adults transitioning from BIC/FTC/TAF.
Interim results from the Positive Perspectives 3 study emphasized that shared decision-making between patients and providers correlated with higher treatment satisfaction and improved health outcomes. Subgroup analyses further underscored the need for expanding awareness and confidence in the “Undetectable = Untransmittable” (U=U) principle.
Collectively, the data presented at IAS 2025 reinforce the safety, durability, and patient-centered benefits of long-acting injectable therapies for HIV treatment and prevention.
Source: ViiV Healthcare presents new data demonstrating positive real-world impact of its innovative long-acting injectables for HIV at IAS 2025. ViiV Healthcare. News release. July 8, 2025. Accessed July 8, 2025. https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-presents-new-data-demonstrating-positive-real-world-impact-of-its-innovative-long-acting-injectables-for-hiv-at-ias-2025/
